Genmab — September 2013
-
OK
-
Iøvrigt godt at se god effekt af ofa-bendamustine, kombinationen testes i rituximab refraktær NHL fase 3 (ligesom GA101)
-
Fedt. Glæder mig til mandag. http://ir.genmab.com/releasedetail.cfm?ReleaseID=790681
-
prøv at lav en googlesøgning på arzerra og specificer den til de sidste 24 timer - den her nyhed har global traction
-
Har lige pløjet mandagens udgave af Børsen igennem - ikke et ord om Genmab
-
-
Hvis du ser på data fra fase 2 studiet, har O-DHAP faktisk væsentligt bedre resultater end R-ICE og R-DHAP, på det grundlag lagde de fase 3 studiet om til udelukkende O-DHAP
-
og vel at mærke!: Conflict-of-interest disclosure: C.G. received research funding from Roche Pharma.
-
-
Hmm - vi har siddet lidt fast siden kl 11. Kan vi ikke få en BTD mere?
-
-
-
-
Bispecific Antibodies Conference | World Bispecific Summit
Advance antibody development and engineering bispecific antibodies at the 16th World Bispecific Summit. Secure your spot with early‑bird pricing.
17th World Bispecifics Summit 2026 (bispecific.com)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind